Literature DB >> 33827450

A randomized trial to evaluate the impact of exercise-based cardiac rehabilitation for the prevention of chemotherapy-induced cardiotoxicity in patients with breast cancer: ONCORE study protocol.

Estíbaliz Díaz-Balboa1,2,3, Violeta González-Salvado4,5, Beatriz Rodríguez-Romero6, Amparo Martínez-Monzonís4,5, Milagros Pedreira-Pérez4,5, Patricia Palacios-Ozores5,7, Rafael López-López5,7, Carlos Peña-Gil4,5, José R González-Juanatey4,5.   

Abstract

BACKGROUND: Anthracyclines and monoclonal antibodies against human epidermal growth factor receptor-2 (HER2) are frequently used to treat breast cancer but they are associated with risk of developing cardiotoxicity. Implementation of cardioprotective strategies as part of breast cancer treatment are needed. To date, a limited number of studies have examined the effectiveness of cardiac rehabilitation programs or exercise programs in the prevention of cardiotoxicity through an integral assessment of cardiac function. The ONCORE study proposes an exercise-based cardiac rehabilitation program as a non-pharmacological tool for the management of chemotherapy-induced cardiotoxicity.
METHODS: The study protocol describes a prospective, randomized controlled trial aimed to determine whether an intervention through an exercise-based CR program can effectively prevent cardiotoxicity induced by anthracyclines and/or anti-HER2 antibodies in women with breast cancer. Three hundred and forty women with breast cancer at early stages scheduled to receive cardiotoxic chemotherapy will be randomly assigned (1:1) to participation in an exercise-based CR program (intervention group) or to usual care and physical activity recommendation (control group). Primary outcomes include changes in left ventricular ejection fraction and global longitudinal strain as markers of cardiac dysfunction assessed by transthoracic echocardiography. Secondary outcomes comprise levels of cardiovascular biomarkers and cardiopulmonary function through peak oxygen uptake determination, physical performance and psychosocial status. Supervised exercise program-related outcomes including safety, adherence/compliance, expectations and physical exercise in- and out-of-hospital are studied as exploratory outcomes. Transthoracic echocardiography, clinical test and questionnaires will be performed at the beginning and two weeks after completion of chemotherapy. DISCUSSION: The growing incidence of breast cancer and the risk of cardiotoxicity derived from cancer treatments demand adjuvant cardioprotective strategies. The proposed study may determine if an exercise-based CR program is effective in minimizing chemotherapy-induced cardiotoxicity in this population of women with early-stage breast cancer. The proposed research question is concrete, with relevant clinical implications, transferable to clinical practice and achievable with low risk. Trial registration ClinicalTrials.gov Identifier: NCT03964142. Registered on 28 May 2019. Retrospectively registered. https://clinicaltrials.gov/ct2/show/NCT03964142.

Entities:  

Keywords:  Anthracyclines; Breast cancer; Cardiac rehabilitation; Cardio-oncology; Cardiotoxicity; Exercise; HER2 overexpression

Year:  2021        PMID: 33827450     DOI: 10.1186/s12872-021-01970-2

Source DB:  PubMed          Journal:  BMC Cardiovasc Disord        ISSN: 1471-2261            Impact factor:   2.298


  43 in total

1.  Expert consensus for multimodality imaging evaluation of adult patients during and after cancer therapy: a report from the American Society of Echocardiography and the European Association of Cardiovascular Imaging.

Authors:  Juan Carlos Plana; Maurizio Galderisi; Ana Barac; Michael S Ewer; Bonnie Ky; Marielle Scherrer-Crosbie; Javier Ganame; Igal A Sebag; Deborah A Agler; Luigi P Badano; Jose Banchs; Daniela Cardinale; Joseph Carver; Manuel Cerqueira; Jeanne M DeCara; Thor Edvardsen; Scott D Flamm; Thomas Force; Brian P Griffin; Guy Jerusalem; Jennifer E Liu; Andreia Magalhães; Thomas Marwick; Liza Y Sanchez; Rosa Sicari; Hector R Villarraga; Patrizio Lancellotti
Journal:  Eur Heart J Cardiovasc Imaging       Date:  2014-10       Impact factor: 6.875

Review 2.  2016 ESC Position Paper on cancer treatments and cardiovascular toxicity developed under the auspices of the ESC Committee for Practice Guidelines: The Task Force for cancer treatments and cardiovascular toxicity of the European Society of Cardiology (ESC).

Authors:  Jose Luis Zamorano; Patrizio Lancellotti; Daniel Rodriguez Muñoz; Victor Aboyans; Riccardo Asteggiano; Maurizio Galderisi; Gilbert Habib; Daniel J Lenihan; Gregory Y H Lip; Alexander R Lyon; Teresa Lopez Fernandez; Dania Mohty; Massimo F Piepoli; Juan Tamargo; Adam Torbicki; Thomas M Suter; Jose Luis Zamorano; Victor Aboyans; Stephan Achenbach; Stefan Agewall; Lina Badimon; Gonzalo Barón-Esquivias; Helmut Baumgartner; Jeroen J Bax; Héctor Bueno; Scipione Carerj; Veronica Dean; Çetin Erol; Donna Fitzsimons; Oliver Gaemperli; Paulus Kirchhof; Philippe Kolh; Patrizio Lancellotti; Gregory Y H Lip; Petros Nihoyannopoulos; Massimo F Piepoli; Piotr Ponikowski; Marco Roffi; Adam Torbicki; António Vaz Carneiro; Stephan Windecker
Journal:  Eur J Heart Fail       Date:  2016-08-27       Impact factor: 15.534

Review 3.  Cardio-Oncology: An Update on Cardiotoxicity of Cancer-Related Treatment.

Authors:  Carrie G Lenneman; Douglas B Sawyer
Journal:  Circ Res       Date:  2016-03-18       Impact factor: 17.367

Review 4.  Curing breast cancer and killing the heart: A novel model to explain elevated cardiovascular disease and mortality risk among women with early stage breast cancer.

Authors:  Amy A Kirkham; Rhys I Beaudry; D Ian Paterson; John R Mackey; Mark J Haykowsky
Journal:  Prog Cardiovasc Dis       Date:  2019-02-22       Impact factor: 8.194

Review 5.  Cardiotoxicity induced by chemotherapy and antibody therapy.

Authors:  Edward T H Yeh
Journal:  Annu Rev Med       Date:  2006       Impact factor: 13.739

6.  Adjuvant trastuzumab in HER2-positive breast cancer.

Authors:  Dennis Slamon; Wolfgang Eiermann; Nicholas Robert; Tadeusz Pienkowski; Miguel Martin; Michael Press; John Mackey; John Glaspy; Arlene Chan; Marek Pawlicki; Tamas Pinter; Vicente Valero; Mei-Ching Liu; Guido Sauter; Gunter von Minckwitz; Frances Visco; Valerie Bee; Marc Buyse; Belguendouz Bendahmane; Isabelle Tabah-Fisch; Mary-Ann Lindsay; Alessandro Riva; John Crown
Journal:  N Engl J Med       Date:  2011-10-06       Impact factor: 91.245

7.  Cardiovascular Disease Mortality Among Breast Cancer Survivors.

Authors:  Patrick T Bradshaw; June Stevens; Nikhil Khankari; Susan L Teitelbaum; Alfred I Neugut; Marilie D Gammon
Journal:  Epidemiology       Date:  2016-01       Impact factor: 4.822

Review 8.  Use of myocardial strain imaging by echocardiography for the early detection of cardiotoxicity in patients during and after cancer chemotherapy: a systematic review.

Authors:  Paaladinesh Thavendiranathan; Frédéric Poulin; Ki-Dong Lim; Juan Carlos Plana; Anna Woo; Thomas H Marwick
Journal:  J Am Coll Cardiol       Date:  2014-04-02       Impact factor: 24.094

Review 9.  Risk of death from cardiovascular disease following breast cancer: a systematic review.

Authors:  S A M Gernaat; P J Ho; N Rijnberg; M J Emaus; L M Baak; M Hartman; D E Grobbee; H M Verkooijen
Journal:  Breast Cancer Res Treat       Date:  2017-05-13       Impact factor: 4.872

10.  Risk prediction model for heart failure and cardiomyopathy after adjuvant trastuzumab therapy for breast cancer.

Authors:  Ghideon Ezaz; Jessica B Long; Cary P Gross; Jersey Chen
Journal:  J Am Heart Assoc       Date:  2014-02-28       Impact factor: 5.501

View more
  4 in total

Review 1.  Heart Failure in Breast Cancer Survivors: Focus on Early Detection and Novel Biomarkers.

Authors:  Dongqing Chen; Conagh Kelly; Tatt Jhong Haw; Janine M Lombard; Ina I C Nordman; Amanda J Croft; Doan T M Ngo; Aaron L Sverdlov
Journal:  Curr Heart Fail Rep       Date:  2021-11-03

2.  Cardio-oncology in Austria: cardiotoxicity and surveillance of anti-cancer therapies : Position paper of the Heart Failure Working Group of the Austrian Society of Cardiology.

Authors:  Jutta Bergler-Klein; Peter P Rainer; Markus Wallner; Marc-Michael Zaruba; Jakob Dörler; Armin Böhmer; Tamara Buchacher; Maria Frey; Christopher Adlbrecht; Rupert Bartsch; Mariann Gyöngyösi; Ursula-Maria Fürst
Journal:  Wien Klin Wochenschr       Date:  2022-05-04       Impact factor: 2.275

3.  Thirty-second sit-to-stand test as an alternative for estimating peak oxygen uptake and 6-min walking distance in women with breast cancer: a cross-sectional study.

Authors:  Estíbaliz Díaz-Balboa; Violeta González-Salvado; Beatriz Rodríguez-Romero; Amparo Martínez-Monzonís; Milagros Pedreira-Pérez; Antonio I Cuesta-Vargas; Rafael López-López; José R González-Juanatey; Carlos Pena-Gil
Journal:  Support Care Cancer       Date:  2022-07-11       Impact factor: 3.359

4.  Cardiotoxicity is mitigated after a supervised exercise program in HER2-positive breast cancer undergoing adjuvant trastuzumab.

Authors:  Quentin Jacquinot; Nathalie Meneveau; Antoine Falcoz; Malika Bouhaddi; Pauline Roux; Bruno Degano; Marion Chatot; Elsa Curtit; Laura Mansi; Marie-Justine Paillard; Fernando Bazan; Loïc Chaigneau; Erion Dobi; Guillaume Meynard; Dewi Vernerey; Xavier Pivot; Fabienne Mougin
Journal:  Front Cardiovasc Med       Date:  2022-09-23
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.